BOLD-100 (Synonyms: NKP-1339 free base; IT-139 free base; KP-1339 free base) |
| Katalog-Nr.GC65318 |
BOLD-100 ist ein Antikrebsmittel auf Rutheniumbasis. BOLD-100 hemmt auch die durch Stress induzierte Hochregulierung von GRP78, stört das Endoplasmatische-Retikulum-(ER)-Homöostase und löst ER-Stress und eine ungefaltete Proteinantwort (UPR) aus. BOLD-100 greift in das komplexe Zusammenspiel zwischen der ER-Stressreaktion, Lysosomendynamik und Autophagieausführung ein.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 783324-98-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BOLD-100 is a ruthenium-based anticancer agent. BOLD-100 also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein response (UPR). BOLD-100 interferes with the complex interplay between ER-stress response, lysosome dynamics, and autophagy execution[1].
[1]. Baier D, et al. The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics. 2022;14(2):238. Published 2022 Jan 20.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *